What the World Cup can teach us ⚽
By NorthX Biologics | June 2026
As football fans around the world follow the excitement of the World Cup, focus naturally turns to what happens on the pitch: the goals, the saves, and the moments that change a match in seconds.
But championships are not won in 90 minutes.
And in biologics development, success is not defined by a single milestone either.
Long before the first whistle, players have trained for thousands of hours, coaches have analyzed opponents, and entire support teams have worked behind the scenes. What spectators see is only the visible result of years of preparation.
The same is true in biologics development and manufacturing.
A successful clinical trial, a regulatory approval, or a commercial launch may appear as defining milestones. But behind every one of those moments lies a much larger story, process development, analytical characterization, scale-up, technology transfer, manufacturing, and quality oversight, often carried out over many years.
Biologics development is a team effort, just like football
Football commentators often focus on star players, but championships are built by teams. Defenders, midfielders, forwards, coaches, analysts, and medical staff all contribute to a shared objective.
Biologics development works much the same way. While every program is unique, it takes a diverse group of specialists to move a molecule from development to manufacturing readiness.
For a bit of World Cup-inspired fun, imagine a biologics program as a football team:
What makes modern biologics development particularly interesting is that the team rarely sits within a single organization. Process scientists, analytical experts, manufacturing specialists, quality professionals, and regulatory strategists often work across company boundaries. The strongest programs are not defined by where expertise resides, but by how effectively it is integrated. In practice, success often comes from building a single team around a shared objective, where distinctions between customer and partner become less important than the science itself.
Of course, the comparison is not perfect. Unlike football, our objective is not to defeat an opponent. Our shared goal is to advance therapies that can ultimately benefit patients.
Reducing risk in biologics development through preparation
One of the most fascinating aspects of elite football is how much effort goes into reducing uncertainty.
Teams study opponents, test tactics, analyse performance data, and prepare for scenarios they may never encounter.
Biologics development follows a remarkably similar principle.
Development teams invest significant effort in understanding how critical process parameters influence product quality attributes, knowing that decisions made during early development can shape manufacturability years later. Media formulation, process characterization, analytical methods, cryopreservation strategies, scale-up approaches, and technology transfer plans are often developed long before the first commercial batch is produced.
Much of this work is invisible from the outside. Yet it is precisely this preparation that helps programs navigate scale-up, regulatory expectations, and manufacturing complexity with greater confidence.
Beyond the final score: what defines success in biologics manufacturing
Whether on a football pitch or in a manufacturing facility, outstanding outcomes rarely happen by chance. They are built through careful preparation and the coordinated efforts of many specialists.
And while there may be no trophy presentation at the end of a successful technology transfer or manufacturing campaign, there is something even more meaningful: helping bring innovative therapies one step closer to the patients who need them.
Biologics manufacturing may never inspire stadium chants, but the outcomes are arguably worth cheering for.
This article compares success in biologics development and manufacturing to World Cup preparation: teamwork, risk reduction, and patient-focused outcomes.